DGX - Quest Diagnostics Gains Momentum: Analyst Highlights Strong Business Trends And Growth Opportunities | Benzinga
Truist Securities analyst David S. MacDonald reiterated a Hold rating on Quest Diagnostics Incorporated (NYSE: DGX), raising the price target to $150 from $145.
MacDonald bumped the price target following management meetings focused on strong base business trends, areas of growth opportunity, ongoing cost/efficiency initiatives, and other puts/takes.
While labor remains a challenge, core growth trends are attractive, M&A and partnership opportunities remain brisk, and the company is seeing improved pricing, according to the analyst.
Financial flexibility remains attractive with solid FCF generation, and the analyst forecasts ongoing capital deployment to augment core trends.
DGX continues to see ...